61 Grants (Page 2 of 3)
2015
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 2R01CA131378-07A1), $389,434USD, 01/01/2008 -- 05/31/2020
 
PDE Inhibition by Sulindac Sulfide Amide Derivatives for Lung Cancer Chemoprevention
Piazza, Gary A and ZHU, BING
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA182941-01A1), $197,273USD, 02/01/2015 -- 01/31/2017
 
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA155638-04), $445,790USD, 08/16/2012 -- 05/31/2016
 
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemoprevention
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA155638-04S1), $121,281USD, 08/16/2012 -- 05/31/2016
2014
Development of a novel sulindac amide for colorectal cancer chemoprevention
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA148817-05), $566,975USD, 08/01/2010 -- 05/31/2016
 
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA155638-03), $406,010USD, 08/16/2012 -- 05/31/2017
2013
Development of a novel sulindac amide for colorectal cancer chemoprevention
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA148817-04S1), $1USD, 08/01/2010 -- 05/31/2015
 
Development of a novel sulindac amide for colorectal cancer chemoprevention
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA148817-04), $1USD, 08/01/2010 -- 05/31/2015
 
MicroRNA, sulindac, and breast cancer chemoprevention
Piazza, Gary A and XI, YAGUANG
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA160280-02), $151,804USD, 03/01/2012 -- 02/28/2015
 
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
Piazza, Gary A and REYNOLDS, ROBERT C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA131378-06), $424,008USD, 01/01/2008 -- 12/31/2013
 
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA155638-02), $336,653USD, 08/16/2012 -- 05/31/2017
 
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA155638-02S1), $160,041USD, 08/16/2012 -- 05/31/2017
2012
Development of a novel sulindac amide for colorectal cancer chemoprevention
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA148817-03S1), $62,504USD, 08/01/2010 -- 05/31/2015
 
Development of a novel sulindac amide for colorectal cancer chemoprevention
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA148817-03), $438,973USD, 08/01/2010 -- 05/31/2015
 
MicroRNA, sulindac, and breast cancer chemoprevention
Piazza, Gary A and XI, YAGUANG
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA160280-01A1), $193,793USD, 03/01/2012 -- 02/28/2014
 
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
Piazza, Gary A and REYNOLDS, ROBERT C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA131378-05), $670,313USD, 01/01/2008 -- 12/31/2013
 
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA155638-01A1), $348,413USD, 08/16/2012 -- 07/31/2017
2011
Development of a novel sulindac amide for colorectal cancer chemoprevention
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA148817-02), $414,101USD, 08/01/2010 -- 05/31/2015
 
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
Piazza, Gary A and REYNOLDS, ROBERT C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA131378-04), $569,429USD, 01/01/2008 -- 12/31/2013
2010
Development of a novel sulindac amide for colorectal cancer chemoprevention
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA148817-01A1), $629,853USD, 08/01/2010 -- 05/31/2011
 
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
Piazza, Gary A and REYNOLDS, ROBERT C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA131378-03), $1USD, 01/01/2008 -- 12/31/2013
2009
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
Piazza, Gary A and REYNOLDS, ROBERT C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA131378-02), $674,075USD, 01/01/2008 -- 12/31/2012
2008
A novel sulindac derivative for colon cancer chemoprevention
Piazza, Gary A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R03CA128021-02), $110,049USD, 04/01/2007 -- 03/31/2010
 
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
Piazza, Gary A and REYNOLDS, ROBERT C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA131378-01), $643,885USD, 01/01/2008 -- 12/31/2012
 
Southern Research Molecular Libraries Screening Center (SRMLSC)
Piazza, Gary A
National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI) (ID: 3U54HG003917-03S2), $1,185,983USD, 07/01/2005 -- 06/30/2009